@article{3051978,
    title = "Could cisplatin as a front-line treatment in childhood non-Hodgkin's
lymphoma be a promising therapy?",
    author = "Papadopoulou, AL and Moschovi, M and Panagopoulou-Cristaki, M and and Anagnostou-Keramida, D and Van Vliet-Constantinidou, C and Botsonis, A and and Tsangaris, GT and Tzortzatou-Stathopoulou, F",
    journal = "Pediatric Hematology and Oncology",
    year = "1999",
    volume = "16",
    number = "4",
    pages = "341-346",
    publisher = "Taylor and Francis Inc.",
    issn = "0888-0018, 1521-0669",
    doi = "10.1080/088800199277173",
    keywords = "childhood; cisplatin; front-line treatment; Ki-1 lymphoma; non-Hodgkin
‘s lymphoma",
    abstract = "Non-Hodgkin’s lymphomas (NHL) were often erroneously diagnosed as other
malignancies and treated accordingly. In this study cisplatin combined
with vincristine, cyclophosphamide, and Adriamycin was weal incidentally
as a front-line treatment in seven children with NHL, because the
initial histologic diagnosis was that of a sarcoma. After reevaluation
three patients had Ki-1 anaplastic large cell lymphoma of T-cell origin,
two abdominal B-cell diffuse high-grade NHL, one mediastinal diffuse
large B-cell lymphoma, and one B-cell lymphoma in the stomach. They
received at least two courses of cisplatin combined regimen and
continued with other protocol for NHL. All patients showed an extremely:
good response from the first course of therapy and the masses vanished
completely. They were followed up for a mean time of 29.5 months and are
all in complete remission. The data indicate that cisplatin is active
against NHL and might be a promising alternative front-like therapy."
}